Insulin resistance, insulin secretion, and glucose tolerance may predict weight change. A total of 1,194 adults aged 39-69 years at baseline (46% with normal glucose tolerance according to World Health Organization criteria, 23% with impaired glucose tolerance, and 31% with type 2 diabetes mellitus who were not taking insulin) were evaluated at baseline (1992-1994) and after 5 years. Baseline insulin sensitivity (S(I)) was measured by means of a 12-sample, insulin-enhanced, frequently sampled intravenous glucose tolerance test. Insulin secretion was assessed in terms of acute insulin response and disposition index, both obtained from the frequently sampled intravenous glucose tolerance test. At follow-up, 25% of subjects had lost more than 2.27 kg (>5 pounds), 38% weighed within 2.27 kg of their baseline weight, and 37% had gained more than 2.27 kg. In separate models, greater weight loss occurred among those with type 2 diabetes than among those with either impaired glucose tolerance or normal glucose tolerance (p < 0.001); baseline acute insulin response and disposition index were positively associated and baseline fasting insulin level was inversely associated with 5-year weight change (p < 0.05 for each; data were adjusted for baseline body mass index and demographic and behavior change variables). Upon simultaneous inclusion of metabolic variables within glucose tolerance status groups, none was a significant predictor of weight loss. Apart from glucose tolerance status itself, measures of insulin metabolism appear to have little effect on weight change over 5 years.

Download full-text PDF

Source
http://dx.doi.org/10.1093/aje/kwg022DOI Listing

Publication Analysis

Top Keywords

glucose tolerance
36
weight change
12
insulin
10
glucose
9
tolerance
9
insulin resistance
8
insulin secretion
8
years baseline
8
normal glucose
8
impaired glucose
8

Similar Publications

Levilactobacillus brevis YT108, identified for its ability to metabolize prebiotic xylo-oligosaccharides (XOS), emerges as a candidate for probiotic use in synbiotic food formulations. This study aimed to investigate the metabolic and genomic traits associated with XOS metabolism in YT108 and to assess its probiotic attributes through whole genome sequencing and in vitro assays. Strain YT108 exhibited robust growth kinetics on XOS as the sole carbon source, with a growth profile comparable to that on glucose, achieving a pH reduction to 4.

View Article and Find Full Text PDF

Introduction: Heart failure with preserved ejection fraction (HFpEF) is characterised by severe exercise intolerance, particularly in those living with obesity. Low-energy meal-replacement plans (MRPs) have shown significant weight loss and potential cardiac remodelling benefits. This pragmatic randomised trial aims to evaluate the efficacy of MRP-directed weight loss on exercise intolerance, symptoms, quality of life and cardiovascular remodelling in a multiethnic cohort with obesity and HFpEF.

View Article and Find Full Text PDF

Introduction: Prolonged sitting can acutely reduce working memory (WM) in individuals with overweight and obesity (OW/OB) who show executive function deficits. Interrupting prolonged sitting with brief PA bouts may counter these effects. However, the benefits of such interventions on behavioral and neuroelectric indices of WM and whether neurocognitive responses are associated with postprandial glycemic responses in young and middle-aged adults with OW/OB remain unknown.

View Article and Find Full Text PDF

The United States Food and Drug Administration approved the xanomeline-trospium combination in September 2024 for treating schizophrenia, based in part on three double-blind, randomized placebo-controlled trials in adults with schizophrenia experiencing acute psychosis. This random-effects model pairwise meta-analysis of those three trials found that xanomeline-trospium was comparable to placebo in terms of all-cause discontinuation, discontinuation rate due to adverse events, Simpson-Angus Scale score change, Barnes Akathisia Rating Scale score change, body weight change, body mass index change, blood pressure change, serum total cholesterol change, blood glucose change, QTc interval changes, and the incidence of headache, somnolence, insomnia, dizziness, akathisia, agitation, tachycardia, gastroesophageal reflux disease, diarrhea, increased weight, and decreased appetite. However, xanomeline-trospium was associated with a higher incidence of at least one adverse event, dry mouth, hypertension, nausea, vomiting, dyspepsia, and constipation, and increased serum triglyceride compared with placebo.

View Article and Find Full Text PDF

Endocrine alterations in patients with pachydermoperiostosis.

J Clin Endocrinol Metab

January 2025

Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Context: Pachydermoperiostosis (primary hypertrophic osteoarthropathy, PHO) usually due to biallelic loss-of-function variants in HPGD and SLCO2A1, has some features overlapping with acromegaly and often referred to endocrinologists. A detailed endocrine assessment is not available for these patients.

Objective: To assess the genetic and endocrine characteristics of PHO patients referred to endocrine centres with a possible diagnosis of acromegaly.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!